Rilpivirine (Edurant, TMC 278)

Published June 20, 2011; Updated June 2018
Susa Coffey, MD
Selected Reference
1. Cohen CJ, Molina JM, Cahn P, et al; ECHO Study Group; THRIVE Study Group. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials.J Acquir Immune Defic Syndr. 2012 May 1;60(1):33-42.